There are 2789 resources available
1092TiP - Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
Presenter: Reinhard Dummer
Session: ePoster Display
1093TiP - An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Presenter: Francesca Aroldi
Session: ePoster Display
1094TiP - A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
Presenter: Andrew Haydon
Session: ePoster Display
1095TiP - Daromun, a dermato-oncology drug in development for stage III and IV melanoma and non-melanoma skin cancers: A clinical overview
Presenter: Katharina Kähler
Session: ePoster Display
1102P - The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
Presenter: Philippe Ruszniewski
Session: ePoster Display
1072P - Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome
Presenter: Emilia Cocorocchio
Session: ePoster Display
1073P - Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial
Presenter: Sapna Patel
Session: ePoster Display
1074P - Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile
Presenter: Michele Del Vecchio
Session: ePoster Display